BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20230101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241030
DTEND;VALUE=DATE:20241102
DTSTAMP:20260515T135955
CREATED:20240719T115454Z
LAST-MODIFIED:20240719T115454Z
UID:39424-1730246400-1730505599@www.pharmajournalist.com
SUMMARY:6th Gene Therapy Analytical Development & CMC Summit
DESCRIPTION:Twelve gene therapies have been approved by the FDA to date to treat a variety of diseases\, including the first ever gene edited therapeutic. The CMC package required to effectively demonstrate safety and efficacy of increasingly complex gene therapy products to regulators needs to keep pace. \nThe 6th Gene Therapy Analytical Development & CMC Summit will unite 250+ analytical development\, CMC\, QC\, and process development experts to showcase innovative analytical and process development methods\, assess their readiness\, and ultimately guarantee safety\, quality\, efficacy\, and consistency of gene therapies to regulators. \nVIEW THE FULL EVENT GUIDE \nJoin your peers this July to: \n\nUnderstand how to transition your potency assay from early to late-stage\nExplore how NGS methods can better inform your genome titers\nAccurately measure partials in your samples\nProduce contaminant-free and high yield vector batches at scale\n\nSecure your place here or get in touch with the team – info@hansonwade.com
URL:http://www.pharmajournalist.com/event/6th-gene-therapy-analytical-development-cmc-summit/
LOCATION:The Westin Copley Place\, 10 Huntington Avenue\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com or Partnership Enquiries: sponsor@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241112
DTEND;VALUE=DATE:20241114
DTSTAMP:20260515T135955
CREATED:20240719T120908Z
LAST-MODIFIED:20240719T120908Z
UID:39429-1731369600-1731542399@www.pharmajournalist.com
SUMMARY:Autoimmunity Pharma & Biotech Partnering Summit
DESCRIPTION:Spurred by George Schett and Andreas Mackensen’s remarkable CAR-T results in SLE\, the immunotherapy revolution for autoimmune diseases is the next “million-dollar question”. \nThe Autoimmunity Pharma & Biotech Partnering Summit is the only event of its kind\, laying enabled partnering on top of hyper-relevant scientific discussion specifically for immune reset and reconstitution therapies. \nVIEW THE FULL EVENT GUIDE \n60+ attending companies across modalities so pharma can decide which horse to back in this quickly evolving space \n1-2-1 meetings bookable via the partnering portal for efficient and high yielding conversations between decision makers \n15 big pharma leads across business development\, search and evaluation\, immunology research and venture giving the best\, most comprehensive opportunity to meet the full teams assessing due diligence and asset synergy \n100% alignment on interests and intentions\, increasing the surface area for synergy in research and collaboration goals \nSecure your place here or get in touch with the team – info@hansonwade.com
URL:http://www.pharmajournalist.com/event/autoimmunity-pharma-biotech-partnering-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com or Partnership Enquiries: sponsor@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241112
DTEND;VALUE=DATE:20241115
DTSTAMP:20260515T135955
CREATED:20240805T120321Z
LAST-MODIFIED:20240805T120321Z
UID:39498-1731369600-1731628799@www.pharmajournalist.com
SUMMARY:Hit ID Summit
DESCRIPTION:Discover the future of drug discovery at the inaugural Hit ID Summit! As chemical libraries and hit screening methods—including DNA-encoded libraries\, high-throughput screening\, fragment-based screening\, and AI—continue to evolve\, now is the time for medicinal chemists\, computational chemists\, and drug discovery leaders and innovators to unite at a dedicated forum. This unique event presents the opportunity to share innovative ideas and actionable insights that will revolutionize hit finding strategies and propel the entire drug development process forward. From delving into the latest hit-finding technologies and methodologies\, bridging the gap from target identification to molecule discovery and transforming hits into promising leads. \nJoin us for an unmissable experience where the biggest names in pharma and biotech come together including AstraZeneca\, Bristol Myers Squibb\, GlaxoSmithKline\, Insitro\, Sanofi & more. This is your chance to stay ahead of the curve and drive innovation in your hit identification and drug discovery strategies. \nDon’t miss out on this unique opportunity to network with over 50 hit strategy specialists and drug discovery experts. With insights from industry giants like AbbVie\, AstraZeneca\, Novartis\, Pfizer\, Sanofi\, and UCB\, gain invaluable knowledge and forge meaningful connections that will take your work to the next level. \nTo know more visit: https://ter.li/fifhhn%20
URL:http://www.pharmajournalist.com/event/hit-id-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241112
DTEND;VALUE=DATE:20241115
DTSTAMP:20260515T135955
CREATED:20240815T164037Z
LAST-MODIFIED:20240815T164037Z
UID:39582-1731369600-1731628799@www.pharmajournalist.com
SUMMARY:8th Dermatology Drug Development Summit
DESCRIPTION:The advanced therapy immuno-inflammatory dermatology market is undergoing unprecedented expansion\, as Johnson & Johnson make a $3.35B play for bispecific candidates\, Alumis secured $259M series C and Galderma\, Incyte\, and Eli Lilly unveil late-breaking data. \nWith a fast-evolving drug development landscape\, remaining at the forefront of promising targets is now more crucial than ever. That’s why we’re delighted to announce the return of the 8th Dermatology Drug Development Summit (November 12-14 | Boston\, MA)\, the definitive industry-led forum uniting 130+ large pharma\, biotech\, and clinician KOLs to discover and develop best-in-class drugs for immuno-inflammatory skin disease. \nExplore the end-to-end conference program here: https://ter.li/5j7wx4 \nFeaturing 30+ expert speakers from the likes of Alys Pharmaceuticals\, LEO Pharma\, Incyte and AbbVie\, program highlights include: \n\n2 NEW tracks on Discovery & Translation to the Clinic and Clinical & Commercial Strategy\, providing more depth of content supporting disease pathogenesis understandings and novel target validation\, through demonstrating durable clinical efficacy whilst navigating nuanced market access challenges\n4 hands-on workshops pairing data-driven insights with collaborative problem-solving discussions to drive therapeutic progress in Hidradenitis Suppurativa\, JAK Inhibitors and Assets Targeting Multiple Indications\, plus laying foundations for Recruitment and Retention finesse.\n\nIncreased drug development landscape visibility\, including clinical case studies from early to late-stage programs\, all with dedicated Q&A time\, for Monoclonal Antibodies\, Oral and Topical Small Molecules\, Oral Peptides\, siRNA Lipid Conjugates\, Bispecific Antibodies and more! \nHere’s a snapshot of who you will meet: \nTakeda | MoonLake Immunotherapeutics | Seagen | Astria Therapeutics | Aditum Bio | Shaperon | Lynk Pharma | CAGE Bio | Sanofi | Edesa Biotech | Arcutis Biotherapeutics | AbbVie | GSK | Carocell Bio | Enveda Biosciences | Zura Bio | Incyte | UNION Therapeutics | Merck | Hudson Therapeutics | J&J | LEO Pharma | Recludix Pharma | Lynk Pharmaceuticals \nStay ahead of the scientific and commercial challenges in inflammatory disease drug development to set yourself up for success in 2025! \nQuick links: Website | Event Guide | Contact Us
URL:http://www.pharmajournalist.com/event/8th-dermatology-drug-development-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241112
DTEND;VALUE=DATE:20241114
DTSTAMP:20260515T135955
CREATED:20240906T115503Z
LAST-MODIFIED:20240906T115503Z
UID:39712-1731369600-1731542399@www.pharmajournalist.com
SUMMARY:Advanced Therapies USA
DESCRIPTION:The Advanced Therapies Congress showcases the future of advanced therapies. Bringing Europe’s largest cell and gene therapy conference and exhibition to Philadelphia\, the event is for the leaders of the world’s ATMP developers and their most senior executives in charge of the latest tech and strategies that are driving the industry forward. This year\, we will be expecting 1000+ attendees\, 200 speakers\, 100+ sponsors and exhibitors\, join us now! \nTo know more visit: www.terrapinn.com/adtusa/pj/index 
URL:http://www.pharmajournalist.com/event/advanced-therapies-usa/
LOCATION:Pennsylvania Convention Center\, Philadelphia
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241113
DTEND;VALUE=DATE:20241115
DTSTAMP:20260515T135955
CREATED:20240815T164748Z
LAST-MODIFIED:20240819T230624Z
UID:39587-1731456000-1731628799@www.pharmajournalist.com
SUMMARY:World Companion Diagnostics & Liquid Biopsy Summit APAC
DESCRIPTION:In the last 12 months\, precision healthcare in the Asia-Pacific region has seen a surge in technology advancements\, including NGS and laboratory developed tests\, approvals such as a companion diagnostic test for lung cancer\, and evolving regulations throughout the region. \nThe World Companion Diagnostics & Liquid Biopsy Summit APAC has been put together to provide a dedicated forum for key stakeholders from biopharma\, diagnostic providers and leading academics to overcome critical challenges in liquid biopsy and companion diagnostic (CDx) testing. \n\nWhere: Conrad Centennial\, Singapore\nWhen: November 13-14\, 2024\nWho: 100+ precision medicine experts from across the APAC region and wider globe\n\nDownload the event agenda here: https://ter.li/3qxsp8 \nThis unique and important forum is uniting experts from Singapore\, Australia\, China\, Japan\, Taiwan\, the USA and more to create a comprehensive framework for successful drug-companion diagnostic co-development and robust biomarker testing to accelerate patient access to personalized healthcare for improved outcomes in the APAC market. \nThis conference is FREE* to attend for drug developers and academics\, see the website for full terms and conditions here: https://ter.li/ewpxoe
URL:http://www.pharmajournalist.com/event/world-companion-diagnostics-liquid-biopsy-summit-apac/
LOCATION:Conrad Centennial\, 2 Temasek Blvd\, Singapore\, 038982\, Singapore
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241118
DTEND;VALUE=DATE:20241121
DTSTAMP:20260515T135955
CREATED:20240808T110613Z
LAST-MODIFIED:20240808T110613Z
UID:39537-1731888000-1732147199@www.pharmajournalist.com
SUMMARY:2nd Donor Selection & Cell Source Summit
DESCRIPTION:Join us at the 2nd Donor Selection & Cell Source Summit – an unparalleled event dedicated to revolutionizing donor testing\, screening\, and cell source selection. This is your chance to be at the forefront of scalable allogeneic manufacturing and streamline both supply chain and process development. \nWhy Attend? \n\nDive Deep: Explore the latest global regulatory requirements and donor testing innovations.\nCutting-Edge Insights: Learn about breakthrough genome sequencing data transforming donor selection.\nForge Connections: Network with leading companies like Bristol Myers Squibb\, ImmuneBridge\, and Deverra Therapeutics.\nExclusive Access: Discover strategies to partner with donation sites and secure access to elite donor pools.\n\nBy refining our donor selection processes today\, we can revolutionize the future of allogeneic therapies and significantly enhance patient outcomes. \nLearn more here.
URL:http://www.pharmajournalist.com/event/2nd-donor-selection-cell-source-summit/
LOCATION:DoubleTree by Hilton Hotel San Diego – Mission Valley\, 7450 Hazard Center Dr\, San Diego\, CA\, 92108\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241119
DTEND;VALUE=DATE:20241122
DTSTAMP:20260515T135955
CREATED:20240805T115824Z
LAST-MODIFIED:20240805T115824Z
UID:39492-1731974400-1732233599@www.pharmajournalist.com
SUMMARY:8th Antifibrotic Drug Development Summit
DESCRIPTION:The landmark FDA approval of the first MASH therapeutic\, the orphan drug designation for systemic sclerosis trials\, and the rapid advancement of IPF treatments through clinical phases have ignited a transformative era in fibrosis research. Now more than ever experts are doubling down on fibrosis. \nAs the focus on innovative therapies intensifies\, there is a pressing need for cutting-edge strategies that can overcome preclinical and clinical challenges has never been more critical. With that\, I’m delighted to announce the return of the 𝗔𝗻𝘁𝗶𝗳𝗶𝗯𝗿𝗼𝘁𝗶𝗰 𝗗𝗿𝘂𝗴 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗦𝘂𝗺𝗺𝗶𝘁 for its 𝟴𝘁𝗵 𝘆𝗲𝗮𝗿 as the fibrosis community’s premier event\, uniting industry experts and key opinion leaders across Pulmonology\, Hepatology\, Rheumatology\, Nephrology\, Cardiology\, and Gastroenterology. \nGathering decision makers to share cross fibrosis insights on innovative strategies to navigate the shared fibrosis challenges from discovery to novel targets\, preclinical models\, biomarkers\, and early-stage clinical trials. Gain exclusive insights and strategies to apply to your own research accelerating the development of truly transformative\, disease-modifying\, ‘antifibrotic’ therapeutics. \nWhether focusing on 𝗜𝗣𝗙\, 𝗠𝗔𝗦𝗛\, 𝘀𝘆𝘀𝘁𝗲𝗺𝗶𝗰 𝘀𝗰𝗹𝗲𝗿𝗼𝘀𝗶𝘀\, 𝗸𝗶𝗱𝗻𝗲𝘆 𝗳𝗶𝗯𝗿𝗼𝘀𝗶𝘀\, 𝗰𝗮𝗿𝗱𝗶𝗮𝗰 𝗳𝗶𝗯𝗿𝗼𝘀𝗶𝘀\, 𝗳𝗶𝗯𝗿𝗼𝘀𝗶𝗻𝗴 𝗜𝗕𝗗 or 𝗮𝗻𝗼𝘁𝗵𝗲𝗿\, this summit is your collective forum to propel innovative and efficacious antifibrotic therapeutics to patients in need. \nJoin us at the 8th AFDD Summit to be part of the conversation\, share your insights\, and discover the innovations that are transforming fibrosis treatment. \nTo know more visit: https://ter.li/01itbv
URL:http://www.pharmajournalist.com/event/8th-antifibrotic-drug-development-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241119
DTEND;VALUE=DATE:20241121
DTSTAMP:20260515T135955
CREATED:20240806T120430Z
LAST-MODIFIED:20240809T122433Z
UID:39503-1731974400-1732147199@www.pharmajournalist.com
SUMMARY:LEAP HR: Emerging Biopharma
DESCRIPTION:Mark your calendars for November because LEAP HR: Emerging Biopharma is back! Returning to Boston from November 19-20\, this event is designed specifically for CHROs\, CPOs\, and Heads of HR at the heart of Emerging Biopharma organizations. Over the course of two days\, we will unite the most senior leaders from Emerging Biopharma companies across the US for unmissable content and invaluable networking opportunities. \nIn today’s rapidly evolving biotech landscape\, there has never been a more crucial time for HR leaders to come together. With limited resources and funding\, the challenges are greater than ever. LEAP HR: Emerging Biopharma provides a platform to address these challenges head-on\, offering strategies to enhance HR efficiency and prepare for a future brimming with investment and growth opportunities. \nThis event is your best opportunity to delve deeply into the pressing issues that senior leaders face daily. Topics will include rethinking organizational efficiencies\, adapting to new agile working methodologies\, and genuinely engaging and retaining critical biopharma talent. Through a series of insightful sessions\, participants will explore how to build high-impact strategies that align closely with business needs and help navigate today’s volatile biotech market. \nUnveiling of 30+ case studies showcasing how HR leaders are overcoming industry challenges\, gain actionable insights into engaging and developing employees\, retaining essential talent\, and preparing for future adversities. By sharing these real-world examples\, you will leave equipped with the tools you need to foster resilience and innovation within their organizations. \nJoin us in Boston this November for LEAP HR: Emerging Biopharma and become part of a dynamic community of HR leaders dedicated to shaping the future of the biopharma industry. Don’t miss this chance to network with peers\, gain fresh perspectives\, and develop strategies that will help your organization thrive in an increasingly competitive market. Be prepared to return to your organization with renewed energy and practical solutions to drive success in the challenging yet promising world of Emerging Biopharma. \nFind out more now: https://ter.li/jqplmd
URL:http://www.pharmajournalist.com/event/leap-hr-emerging-biopharma/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="LEAP HR":MAILTO:leaphr@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241120
DTEND;VALUE=DATE:20241122
DTSTAMP:20260515T135955
CREATED:20240920T113804Z
LAST-MODIFIED:20240924T114350Z
UID:39796-1732060800-1732233599@www.pharmajournalist.com
SUMMARY:Portfolio Strategy & Decision Making for Biopharma Summit
DESCRIPTION:Join us at the inaugural Portfolio Strategy & Decision Making for Biopharma Summit – the must-attend event for pharma and biotech leaders seeking to sharpen their portfolio strategies in today’s dynamic market. \nGain exclusive insights into leveraging advanced data analytics\, forecasting tools\, and innovative approaches to enhance decision-making. This summit will showcase real-world case studies and best practices from both established big pharma and agile biotech companies\, helping you navigate market volatility with confidence. \nNetwork with over 60 industry leaders and engage in discussions focused on boosting cross-functional collaboration and exploring partnership opportunities. Learn how to align stakeholders\, mitigate risks\, and drive sustainable growth through strategic portfolio management. \nIn an era of rapid change and unprecedented challenges in the biopharma market\, this event is essential for staying ahead. Don’t miss the opportunity to equip yourself with the tools and knowledge to adapt\, respond\, and implement strategies that ensure portfolio success. \nKey Themes Include: \n\nAdvanced data analytics for better decision-making\nRisk mitigation and portfolio optimization\nCross-functional collaboration and partnerships\n\nJoin us to analyze\, adapt\, and respond to today’s biopharma challenges—position yourself for success!
URL:http://www.pharmajournalist.com/event/portfolio-strategy-decision-making-for-biopharma-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241121
DTEND;VALUE=DATE:20241123
DTSTAMP:20260515T135955
CREATED:20240904T114349Z
LAST-MODIFIED:20240904T121218Z
UID:39681-1732147200-1732319999@www.pharmajournalist.com
SUMMARY:3rd Liquid Biopsy Surveillance Summit
DESCRIPTION:Liquid biopsies are revolutionizing clinical trials\, emerging as a game-changing diagnostic tool for monitoring molecular residual disease and detecting disease resistance. This breakthrough enables precise patient stratification\, ensuring they receive the most effective and safe treatments. The 3rd Liquid Biopsy Surveillance Summit returns as the leading East Coast forum solely dedicated to MRD detection in clinical trials to improve stage response monitoring to get patients earlier access to precision treatments. \n \nExpect to hear critical insights from leading biopharma\, oncologists and diagnostic providers to utilise liquid biopsies as surrogate endpoints in clinical trials\, guide dosing decisions and enable the development of precise drugs for patients with unmet needs in oncology and beyond. \nJoin your peers from Biomarker\, Translational and Clinical Development teams to more accurately monitor drug response through MRD assessments for improved treatment regimens from early to late stage clinical trials to improve patient outcomes. \nThis event is free to attend* if you work for a drug developer\, researcher\, or academic institution. \nDownload the event guide for full details: https://ter.li/ig2qtr \n*View the website for full T&Cs: https://ter.li/h7ri3w
URL:http://www.pharmajournalist.com/event/3rd-liquid-biopsy-surveillance-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241126
DTEND;VALUE=DATE:20241129
DTSTAMP:20260515T135955
CREATED:20240906T130002Z
LAST-MODIFIED:20240906T130002Z
UID:39730-1732579200-1732838399@www.pharmajournalist.com
SUMMARY:GPCRs-Targeted Drug Discovery Summit Europe
DESCRIPTION:As structural biology tools and screening technologies advance\, the GPCR super family continues to be a hot area of drug discovery\, with the potential to treat a plethora of diseases. For the first time ever\, the GPCRs-Targeted Drug Discovery Summit Europe is coming to London\, with the aim of overcoming pharmacology challenges and advancing the next wave of GPCR drug discovery. \nThis November\, leading European biopharma experts and trail-blazing opinion leaders of academia are uniting under one roof at this inaugural Meeting to share data\, discuss the latest advances in drug discovery. This Summit will deconvolute signalling bias\, reveal novel targets for successful therapeutic interventions and fast-track structurally guided GPCR drug discovery across inflammatory\, cardiovascular and metabolic indications and beyond. \nBringing together technical experts from Eli Lilly\, AstraZenenca\, Roche\, ThirtyFiveBio\, OMass Therapeutics and more\, this Meeting aims to unlock previously undruggable targets\, reveal the significance of genetic variants of GPCRs\, showcase ground-breaking drug discovery tools and streamline the translation of small molecules and biologics into clinically successful therapies. \nJoin 70+ Senior Scientists\, Heads and Directors of Drug Discovery\, Biology\, Chemistry and Pharmacology for 3 days of technical and data driven case studies and discussions\, enabling you and your team to accelerate novel GPCR-targeted drug discovery. \nTo know more visit: https://ter.li/os0qc7
URL:http://www.pharmajournalist.com/event/gpcrs-targeted-drug-discovery-summit-europe/
LOCATION:Millennium Hotel and Conference Centre Gloucester\, 4-18 Harrington Gardens\, South Kensington\, London\, SW7 4LH\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR